Piper Sandler Maintains an Overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is among the 20 Best Performing Stocks in 2025.

On December 17, 2025, TheFly reported that Piper Sandler maintained its Overweight rating for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) and lifted its price objective from $70 to $100. The company has introduced Redemplo for Familial Chylomicronemia Syndrome, as stated by analyst Edward Tenthoff. Piper anticipates at least $625,000 in U.S. FCS sales in Q4 2025 and $12.3 million in 2026. The business stated that these projections could be conservative due to Redemplo’s greater potency, quarterly dosing schedule, and $60,000 lower yearly price compared to Ionis’ Tryngolza. Furthermore, Piper showed confidence that the firm will disclose positive Phase III Redemplo data in cases of severe hypertriglyceridemia in Q3 2026, with the possibility of a blockbuster label expansion in 2027.

Separately, on January 7, 2026, Morgan Stanley maintained its Equal Weight rating while increasing its price objective for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)  from $48 to $81. The firm noted early ARO-INHBE and ARO-ALK7 monotherapy data, claiming that the findings verify the fat loss objective and show prospects in obesity, which it sees as an additional value driver.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is an American biotechnology firm.

While we acknowledge the potential of ARWR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None